Fractalkine Binding Aptamers with Modified Nucleic Acid Structures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective targeting of fractalkine, a chemokine involved in inflammatory diseases and cancer, due to insufficient affinity of existing binding molecules.
Innovation Solution
Development of polynucleotides, specifically aptamers with high affinity for fractalkine, which can bind with a dissociation constant of less than 40 nM, including modifications such as nucleic acid sugar and backbone modifications, and covalently attached tails for enhanced interaction and delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing binding molecules are used to target fractalkine, then the therapeutic approach is simple, but the affinity is insufficient for effective cellular applications
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of nucleic acid molecules through sugar modifications (e.g., 2'-O-methyl, fluoro sugars), backbone modifications (e.g., phosphorothioate, methylphosphonate), and adding covalently attached tails (e.g., polyethylene glycol, cholesterol, biotin). These structural parameter changes dramatically increase binding affinity to fractalkine while maintaining the fundamental aptamer structure, resolving the contradiction between simplicity and effectiveness.
Solution Approach 2:
The patent creates composite molecules by combining nucleic acid sequences with modified sugars, modified backbones, and various tail groups. These composite structures integrate multiple functional elements into a single molecule that achieves high affinity binding to fractalkine, overcoming the limitation of simple unmodified nucleic acids while providing a systematic solution rather than random complexity.
2Reliability
If unmodified polynucleotides are used, then the molecular structure is simple, but the binding affinity and stability are insufficient
Solution Approach 1:
The patent systematically modifies nucleic acid parameters including sugar pucker (via 2'-O-methyl and fluoro modifications), backbone charge and flexibility (via phosphorothioate and methylphosphonate), and hydrophobicity (via attached tails). These parameter changes enhance both binding affinity and nuclease resistance, demonstrating that controlled structural complexity improves reliability rather than hindering it.
Solution Approach 2:
The patent divides the polynucleotide structure into distinct functional segments: the core binding sequence, modified sugar regions, modified backbone regions, and terminal or internal tail attachments. This segmentation allows each component to be optimized independently for specific functions (binding, stability, cellular uptake) while working together as an integrated high-affinity molecule.
3Reliability
If high affinity binding is achieved through modifications, then the therapeutic efficacy is improved, but the manufacturing complexity increases
Solution Approach 1:
The patent modifies nucleic acid parameters using well-established chemical modification techniques that are compatible with automated oligonucleotide synthesis. The modifications (sugar, backbone, tails) can be incorporated during solid-phase synthesis using standard phosphoramidite chemistry, allowing high-affinity molecules to be manufactured with relatively simple, scalable processes despite the increased molecular complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers effectively target fractalkine, offering potential therapeutic and diagnostic applications by specifically binding to the chemokine domain, potentially blocking CX3CR1-fractalkine interactions and providing a tool for manipulating fractalkine-related diseases.
Implementation Method 1
polynucleotides that bind to fractalkine... bind to human fractalkine with a KD of less than 40 nM
Data Source
AI summary
Provided herein are polynucleotides that bind to fractalkine. In one embodiment, a polynucleotide includes the polynucleotide sequence SEQ ID NO:1 or a sequence having at least 80% identity to SEQ ID NO:1. Also provided herein are structures that include such a polynucleotide present on its surface, including 2-dimentional and 3-dimentional structures. Also provided are compositions that include such a polynucleotide, and methods for using the polynucleotides.